PLUS News - Candlesense

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures

How does the 75% clinical benefit rate compare to existing therapies and pipeline competitors, and what impact could this have on market share and partnership opportunities? What are the regulatory pathways and expected timeline for FDA approval of REYOBIQ in leptomeningeal metastases, and how might that influence near‑term price volatility? How will the positive REYOBIQ trial results affect Plus Therapeutics' revenue forecasts and valuation multiples?

Clinical trials

5 days ago

Plus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

What are the implications for future regulatory or compliance filings if the equity level fluctuates? How might this compliance news influence analyst coverage or sentiment toward PLUS in the near term? Are there any red flags or hidden risks associated with meeting Nasdaq’s equity requirement solely through accounting adjustments?

Compliance

8 days ago

ePlus Reports First Quarter Fiscal Year 2026 Financial Results

~ Announces Initial Common Stock Quarterly Dividend of $0.25 Per Share and New Stock Repurchase Program ~ First Quarter Fiscal Year 2026 Consolidated net sales increased 19.0% to $637.3 million fro...

How might the market react to the combination of dividend initiation and share buyback in terms of valuation multiples? What potential macro or sector risks could offset the positive momentum shown in this quarter? Is the company’s balance sheet strong enough to support the dividend and repurchase program without compromising growth initiatives?

Earnings

15 days ago

ePlus Announces Initiation of Quarterly Cash Dividend

HERNDON, Va., Aug. 7, 2025 /PRNewswire/ -- ePlus inc. (NASDAQ: PLUS), a leading provider of technology solutions, today announced that its Board of Directors has declared its first quarterly divide...

How does the dividend announcement align with ePlus's long‑term earnings guidance and outlook? What is the expected ex‑dividend date and how might it affect trading volume and price volatility around that date? Will the dividend initiation affect the company's ability to fund future growth initiatives or M&A activity?

Dividends

15 days ago